Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881569 · ClinicalTrials.gov registry record · Phase 1
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00881569 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 2 participants.
The verdict
NCT00881569, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug. Participants who have not progressed while receiving CS-7017 will continue to benefit from longer administration of the agent.
Interventions
- DRUG CS-7017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881569
The ClinicalTrials.gov registry entry for NCT00881569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CS-7017 is the first listed.
NCT00881569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00881569 about?
NCT00881569 is a clinical study titled "Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017". This is a study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug. Participants who have not progressed while receiving CS-7017 will continue to ...
What is the current status of trial NCT00881569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2009-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00881569?
The interventions under investigation include: CS-7017 (DRUG).
Who is sponsoring clinical trial NCT00881569?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.